Sparkle Clean Tech Licenses Oil & Gas Water Treatment Technologies from Siemens Energy, Inc.
20.1.2025 12:03:00 CET | Business Wire | Press release
This License expands Sparkle's portfolio for sustainable, integrated water solutions that support oil and gas exploration and production and support customers' waste and efficiency goals.
Sparkle Clean Tech, a global provider of process technologies and value-driven energy solutions for upstream Oil and Gas customers, is pleased to announce that it has reached an agreement with Siemens Energy to license Intellectual Property from their upstream oil and gas related water solutions technology portfolio. The license includes technologies for primary, secondary and tertiary oily water treatment, such as Corrugated Plates, Hydrocyclones, Flotation Units, Walnut Shell filters, as well as regenerable membrane-based treatment technologies. This license includes intellectual property such as patents, copyrights and trade secrets. The technologies effectively address the water and wastewater needs of the oil and gas industry.
Sparkle Clean Tech will license Siemens Energy's Monosep™ Nutshell Filtration; Perfomedia™ adsorption technology; Veirsep™ and Spinsep™ Flotation with Brise DGF Pumps or Eductors; FoldedFlo™ DAF; Liquid/Liquid Hydro cyclones with TL1.05™ Liners; and Corrugated Plate separators, along with the associated intellectual property.
The integration of these technologies will expand Sparkle Clean Tech's portfolio of sustainable and integrated offerings into the treatment of water and wastewater produced in Oil & Gas exploration and production facilities.
Mike Foster, Director of Sparkle Clean Tech, stated, "Water and wastewater management in Oil & Gas exploration and production is critical for our customers who are looking for answers to improve efficiency, make their operations more sustainable, and comply with environmental regulations and standards. This license adds to our growing integrated technology portfolio and provides yet another sustainable solution for our customers."
Sumeet Mehra, CEO Sparkle Clean Tech, stated further "We are thrilled to announce the licence of Siemens Energy's oil and gas water and wastewater treatment technologies. This strategic move reinforces our commitment to providing comprehensive and sustainable solutions to our customers in the oil and gas industry. The addition of these cutting-edge technologies to our portfolio not only expands our capabilities but also strengthens our position as a leader in integrated water solutions. We are confident that these licenses will play a significant role in supporting our customers' waste and efficiency goals while contributing to the preservation of our environment."
The licensed portfolio of technologies focuses on the treatment of oil & gas wastewater from production wells, while the Brise & Perfomedia process offers an efficient wastewater treatment solution designed to remove pollutants from produced wastewater. Both processes offer significant advancements in waste management within the oil and gas industry.
Sparkle Clean Tech is committed to driving innovation and sustainability within the oil and gas sector. By licensing Siemens Energy's upstream water treatment technologies, Sparkle Clean Tech aims to offer comprehensive solutions that support customers' waste and efficiency goals, while also contributing to environmental preservation.
About Sparkle Clean Tech:
Sparkle Clean Tech is a global provider of process technologies and value-driven energy solutions for upstream Oil and Gas customers. With a focus on sustainability and innovation, Sparkle Clean Tech aims to optimize operations and support customers' environmental goals while driving efficiency and profitability.
Sparkle Clean Tech’s other solutions include treatment technologies for water and wastewater management. Utilizing specialized Ultrafiltration, Reverse Osmosis, Desalination, and High Purity Water technologies, Sparkle addresses the needs of diverse industries including Lithium, Microelectronics, Mining among others. With a global customer footprint, Sparkle has executed several projects in the Americas, Europe, Asia, and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120193068/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom